Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | -- |
| Low | -- |
| Bid | -- |
| Offer | -- |
| Previous close | 0.00 |
| Average volume | -- |
|---|---|
| Shares outstanding | 192.32m |
| Free float | 150.39m |
| P/E (TTM) | -- |
| Market cap | 765.45m USD |
| EPS (TTM) | -0.2219 USD |
Data delayed at least 20 minutes, as of Jan 31 2025.
More ▼
Announcements
- Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
- Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
- Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
- Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
- Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
- Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
- Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
More ▼
